New Silk Road Capital
新丝路资本
elsewhere's corpus does not cover New Silk Road Capital as a subject in its own right. The fund appears only in passing as a co-investor or follower in deals led by others: it followed on in DigiSight Medical's Pre-A+ round in 2023 alongside Linear Capital and others , and participated in DeepWise's Series C1 in 2021 . No founding date, team, strategy, or fund size is stated in these references.
AI-generated — may contain errors, please verify.
New Silk Road CapitalFund
新丝路资本
渲染中…
Mentioned in 3 articles
Coverage
Linear Capital's Pre-A lead portfolio company **DigiSight Medical** has closed a multi-million-yuan Pre-A+ round, with existing investor Linear Capital continuing to back the company.
Accelerating clinical trials and R&D for ophthalmic and microsurgical robotic products.
2022, the Door Opens to the Future | 5Y News Monthly
The big news from last month.
5Y News | 5Y Capital Portfolio Company Deepwise Completes Nearly RMB 100 Million Series C1 Funding Round
Bringing AI medical imaging into grassroots healthcare.
